AU2021238632A1 - Salts and crystalline forms of a TAAR1 agonist - Google Patents

Salts and crystalline forms of a TAAR1 agonist Download PDF

Info

Publication number
AU2021238632A1
AU2021238632A1 AU2021238632A AU2021238632A AU2021238632A1 AU 2021238632 A1 AU2021238632 A1 AU 2021238632A1 AU 2021238632 A AU2021238632 A AU 2021238632A AU 2021238632 A AU2021238632 A AU 2021238632A AU 2021238632 A1 AU2021238632 A1 AU 2021238632A1
Authority
AU
Australia
Prior art keywords
hydrochloric acid
disorders
acid salt
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021238632A
Other languages
English (en)
Inventor
Kirsten Andrea GRAESER
Urs Schwitter
Frank Stowasser
Florence Nicole Antoinette TIXERONT
René Trussardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2021238632A1 publication Critical patent/AU2021238632A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021238632A 2020-03-19 2021-03-17 Salts and crystalline forms of a TAAR1 agonist Pending AU2021238632A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
AU2021238632A1 true AU2021238632A1 (en) 2022-07-14

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021238632A Pending AU2021238632A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a TAAR1 agonist

Country Status (13)

Country Link
US (1) US20230120311A1 (https=)
EP (1) EP4121428B1 (https=)
JP (2) JP2023517729A (https=)
KR (1) KR20220155575A (https=)
CN (1) CN115279752A (https=)
AU (1) AU2021238632A1 (https=)
BR (1) BR112022016746A2 (https=)
CA (1) CA3166331A1 (https=)
ES (1) ES3044409T3 (https=)
IL (1) IL294301A (https=)
MX (1) MX2022010794A (https=)
TW (1) TWI874616B (https=)
WO (1) WO2021185878A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023323858A1 (en) * 2022-08-12 2024-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2017157873A1 (en) * 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Also Published As

Publication number Publication date
JP2023517729A (ja) 2023-04-26
CA3166331A1 (en) 2021-09-23
EP4121428A1 (en) 2023-01-25
BR112022016746A2 (pt) 2022-10-11
WO2021185878A1 (en) 2021-09-23
KR20220155575A (ko) 2022-11-23
US20230120311A1 (en) 2023-04-20
EP4121428B1 (en) 2025-08-13
IL294301A (en) 2022-08-01
TW202140466A (zh) 2021-11-01
ES3044409T3 (en) 2025-11-26
EP4121428C0 (en) 2025-08-13
TWI874616B (zh) 2025-03-01
CN115279752A (zh) 2022-11-01
MX2022010794A (es) 2022-09-27
JP2025166092A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
US20230120311A1 (en) Salts and crystalline forms of a taar1 agonist
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
JP6995043B2 (ja) リジン特異的デメチラーゼ－１の阻害剤を含む組成物
WO2019191620A1 (en) Crystalline forms of modulators of cftr
EP3597189A1 (en) Crystalline compounds
JP5997162B2 (ja) アプレピタントｌ−プロリン組成物および共結晶
CN104159584A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2496079A1 (en) Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2022043755A2 (en) Crystalline edg-2 receptor antagonist and methods of making
HK40074347A (en) Salts and crystalline forms of a taar1 agonist
US10513500B2 (en) Crystalline forms of Lesinurad
US9266822B2 (en) Solid forms of tacedinaline
CA3255634A1 (en) Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
HK40077679A (en) Crystalline compounds
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
HK1187554B (en) Aprepitant l-proline composition and cocrystal
HK1223101A1 (zh) Gdc-0032的多晶型物、其制备方法和药物用途